



2019-2020

Annual Report



In 2019-2020, BioCanRx, Canada's Immunotherapy Network, continued to advance to the clinic the most promising cancer biotherapeutics designed to save lives and enable a better quality of life.



47 Active Network Investigators

90 Collaborators

In the fifth year of the network's first cycle, we accelerated mature Canadian technologies from the lab into early phase clinical testing by providing researchers across Canada with access to funding, expertise, training and manufacturing facilities. This year, 23 research projects (of 45 funded in Cycle I) and three core facilities were active including several projects that have moved through our pipeline model including Catalyst, Enabling, Clinical Trials and Clinical, Social and Economic Impact projects.



23 Active Research Projects

3

Active Core Facilities



\$19,846,669

Partner Funds Leveraged

BioCanRx prepared for Cycle II network renewal with a Call for Letters of Intent looking for the most promising immunotherapy-based products and platforms including sustainable solutions for their delivery and uptake in Canada. We received 42 LOIs and 25 of these were invited to full application. The applicants, made up of multidisciplinary research teams at academic institutions across the country, are collaborating with several Canadian biotech partners.



We are particularly proud that BioCanRx's made-in-Canada Chimeric Antigen Receptor T-Cell (CAR T) research program opened the first clinical trial that uses Canadian-made CAR T-cells with sites in Ottawa and Vancouver.

This biomanufacturing investment could lead to even better CAR T therapies that target more types of cancer and more research innovations available to Canadian patients right here in Canada.



Credit: BC Cancer



2 Licenses Granted

1 License in Negotiation

133 Publications

4 Patent Applications

6 New Innovations

2 Spinout Companies



186

Active HQP



15


Summer Studentships

4

Workshops



Another highlight in 2019-20 was our work with the Ottawa Hospital Research Institute's Biotherapeutics Manufacturing Centre (BMC) in establishing a partnership with Alberta Cell Therapy Manufacturing to expand and maximize our viral vector, and other virus-based manufacturing capacity, in Canada.



Training the next generation of immunotherapy researchers and biotechnology industry workers remains a cornerstone of BioCanRx. This year, 186 active Highly Qualified Personnel worked with BioCanRx researchers across the country and took part in webinars, workshops, committees, travel awards and showcased their research at the Summit for Cancer Immunotherapy (Summit4CI) held in Victoria, BC.



115
Travel Awards



300

Summit
Delegates



28

International
Speakers

Summit4CI brought together 300 delegates including leading scientists, clinicians, trainees, economists and representatives from industry, patient groups, charities and government to explore the latest immunotherapy developments from scientific, clinical, patient and industry perspectives. For the third year, the Summit welcomed the BioCanRx-Cancer Stakeholder Alliance (CSA) Learning Institute. Patient/public leaders and HQP academic scholars joined in an interactive and collaborative knowledge exchange program. Participants become familiar with research concepts in immuno-oncology, developed knowledge translation skills, networked, and created partnerships.



**Read the 2019
Learning Institute
Dissemination
Report**



**View Clinical
Trial Map**



Along with the Learning Institute, BioCanRx's commitment to the patient voice included a patient-researcher roundtable and a public forum in partnership with the BC Cancer Foundation. This year we continued joint activities with the CSA, such as the launch of a clinical trial map on biocanrx.com.

Patient-Focused Initiatives 2019-20

Public Forum in Victoria, BC

Cancer Stakeholder Alliance annual meeting

The Learning Institute

Patient-Researcher Roundtable


GO-CART study published

BioCanRx Clinical Trials: Online map & fact sheets

BioCanRx Researcher Database



**View
Researcher
Database**



Many organizations and individuals contributed this year to the success of BioCanRx. We thank the Government of Canada's Networks of Centres of Excellence program for funding support. We are grateful to the Ottawa Hospital Research Institute for being our host institution and for its ongoing support of cancer immunotherapy research.

We also would like to thank our Board of Directors, Research Management Committee, network members, researchers, HQP, members of our Cancer Stakeholder Alliance, our industry partners and the network's administrative staff.



As BioCanRx begins a new three-year cycle, we remain committed to leading the translation, manufacture and adoption of leading-edge cancer immunotherapies with our vision to cure Canadian cancer patients and enhance the quality of life of those living with cancer.



Ken Newport, Chair,
Board of Directors



Stéphanie Michaud
President and CEO



John C. Bell
Scientific Director

**BIOCANRX: BIOTHERAPEUTICS
FOR CANCER TREATMENT**

**STATEMENT OF REVENUE AND
EXPENDITURES**

YEAR ENDED MARCH 31, 2020

**BIOCANRX: BIOTHÉRAPIES
POUR LE TRAITEMENT DU CANCER**

ÉTAT DES RÉSULTATS

EXERCICE TERMINÉ LE 31 MARS 2020

	2020	2019	
REVENUE			REVENUS
Networks of Centres of Excellence grant (Note 3)	\$ 4,432,385	\$ 5,262,473	Subvention des Réseaux de centres d'excellence du Canada (note 3)
Contributed services in-kind (Note 7)	66,000	66,000	Apports en nature (note 7)
Recognition of deferred capital contributions (Note 4)	10,500	18,000	Apports reportés afférents aux immobilisations constatés (note 4)
Sponsorship and event registration fees	202,505	214,962	Frais d'inscription aux événements et commandites
Miscellaneous (Note 7)	21,874	63,475	Divers (note 7)
	4,733,264	5,624,910	
EXPENDITURES			DÉPENSES
Mission Fulfillment:			Réalisation de la mission:
Research grants (Note 5)	2,878,278	3,877,653	Subventions de recherche (note 5)
Research travel	40	5,406	Frais de déplacement pour la recherche
Training (Note 5)	219,223	200,662	Formation (note 5)
Cancer summit (Note 5 and Note 7)	559,769	618,663	Sommet sur le cancer (note 5)
Communications (Note 5 and Note 7)	156,827	156,404	Communications (note 5)
Knowledge mobilization (Note 5)	108,315	20,675	Mobilisation des connaissances (note 5)
Commercialization core facility	27,609	3,000	Centre de commercialisation
	3,950,061	4,882,463	
Governance and Administration:			Gouvernance et administration:
Amortization	16,908	22,875	Amortissement
Networking	69,283	39,230	Réseautage
Operating (Note 7)	127,517	111,145	Opérations (note 7)
Professional and consulting fees	91,569	49,939	Honoraires professionnels et de consultation
Salaries and benefits (Notes 5, 6 and 7)	304,903	277,154	Salaires et avantages sociaux (notes 5, 6 et 7)
Recruiting	3,288	426	Recrutement
Travel	39,881	18,079	Frais de déplacement
	653,349	518,848	
	4,603,410	5,401,311	
EXCESS OF REVENUE OVER EXPENDITURES	\$ 129,854	\$ 223,599	EXCÉDENT DES REVENUS SUR LES DÉPENSES

**BIOCANRX: BIOTHERAPEUTICS
FOR CANCER TREATMENT**

STATEMENT OF FINANCIAL POSITION

MARCH 31, 2020

**BIOCANRX: BIOTHÉRAPIES
POUR LE TRAITEMENT DU CANCER**

BILAN

31 MARS 2020

	2020	2019	
ASSETS			ACTIF
CURRENT ASSETS			ACTIF À COURT TERME
Cash	\$ 4,901,054	\$ 4,965,080	Encaisse
Amounts receivable (Note 7)	30,311	42,793	Comptes à recevoir (note 7)
Prepaid expenditures	35,973	39,867	Dépenses payées d'avance
	4,967,338	5,047,740	
PROPERTY AND EQUIPMENT (Note 2)	10,887	15,897	IMMOBILISATIONS (note 2)
	\$ 4,978,225	\$ 5,063,637	
LIABILITIES AND NET ASSETS			PASSIFS ET ACTIFS NETS
CURRENT LIABILITIES			PASSIF À COURT TERME
Accounts payable			Comptes fournisseurs
and accrued liabilities (Notes 7 and 9)	\$ 161,403	\$ 95,005	et charges à payer (notes 7 et 9)
Government remittances payable	425	204	Remises gouvernementales à payer
Deferred revenue	11,000	-	Revenus perçus d'avance
	172,828	95,209	
DEFERRED CONTRIBUTIONS (Note 3)	4,165,960	4,448,345	APPORTS REPORTÉS (note 3)
DEFERRED CAPITAL			APPORTS REPORTÉS AFFÉRENTS
CONTRIBUTIONS (Note 4)	-	10,500	AUX IMMOBILISATIONS (note 4)
	4,165,960	4,458,845	
NET ASSETS			ACTIFS NETS
Invested in property and equipment	10,887	5,397	Investis dans les immobilisations
Unrestricted	628,550	504,186	Non affectés
	639,437	509,583	
	\$ 4,978,225	\$ 5,063,637	

Economic dependence (Note 8)
Financial instruments (Note 9)
Subsequent event (Note 10)

ON BEHALF OF THE BOARD:

 Director
 Director

Dépendance économique (note 8)
Instruments financiers (note 9)
Événements postérieurs (note 10)

AU NOM DU CONSEIL

_____, Administrateur(trice)
_____, Administrateur(trice)

For full financial disclosure information:
<https://biocanrx.com/new-events/publications>

Afin de recevoir l'information financière:
<https://biocanrx.com/nouvelles-et-evenements/publications-media?lang=fr>

Subscribe to
our newsletter:

biocanrx.com



YouTube

